about
Conventional vs. tablet computer-based patient education following lung transplantation--a randomized controlled trialThe lung transplant patient in the ICU.Safety and efficacy of outpatient bronchoscopy in lung transplant recipients - a single centre analysis of 3,197 proceduresRemission achieved in refractory advanced takayasu arteritis using rituximab.Therapeutic approach to respiratory infections in lung transplantation.Course and treatment of chronic hepatitis E virus infection in lung transplant recipients.Impact of GB virus C viraemia on clinical outcome in HIV-1-infected patients: a 20-year follow-up study.Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock.No increased incidence for GB-virus C infection in a cohort of HIV-positive lymphoma patients.Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients.Biodegradable stent for vanishing bronchus syndrome after lung transplantation.Inhaled colistin following lung transplantation in colonised cystic fibrosis patients.Low exercise tolerance correlates with reduced inspiratory capacity and respiratory muscle function in recipients with advanced chronic lung allograft dysfunction.The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation.Early donor-specific antibodies in lung transplantation: risk factors and impact on survival.Paclitaxel-coated balloons in refractory nonanastomostic airway stenosis following lung transplantation.Introduction of the lung allocation score in Germany.Breath volatile organic compounds of lung transplant recipients with and without chronic lung allograft dysfunction.Significance of new lung infiltrates in outpatients after lung and heart-lung transplantationCatheter Fragmentation and Local Lysis in Two Lung Transplant Patients with Pulmonary Embolism
P50
Q27317020-91C1419D-079D-4A7C-BD05-E3DB24C447F9Q33402479-A66EF08C-28AE-43E6-B3E0-A056BD5B110BQ40477059-7A20035E-3A85-407F-8069-77B89BB9F4EFQ41846985-C9B8F98E-FBC1-42A7-8426-0631D24F59D1Q42205282-10A880D0-5513-47FE-B756-496C5D9B3A87Q42242623-5E2AA9D4-5463-491C-9ACD-D1D7FF4DC119Q42263062-3466C953-9706-4552-A64B-8A0F0E83D6B8Q42654082-BED79CA5-0977-4A19-9182-8832654B779EQ42999337-EF326438-1643-471C-8AAE-8EBA20758B80Q44793703-0513DB01-221E-4D6E-B3F9-A96B7C82D230Q45843488-D7752121-7B6D-4B67-A6A1-3E29475A055FQ47886130-DF7488D4-72B5-461A-90F9-AE6C2182DF24Q48259655-36B4B51A-A4DB-4331-9B0E-73592E37E982Q48921974-BE5532C2-88B0-4C76-90C8-138C18705318Q51366236-15063D6C-7391-4CD3-B484-30EF497C4D0FQ51707524-3153CDE5-10C6-481B-913C-7C0B26B63114Q51708600-A3743B9A-5792-479E-9950-7720C9AF3849Q51721925-45840FAC-7C3B-430E-9B0D-CDB27B2F3BB4Q54208967-BC8291EF-AFA9-407E-9525-7CA5FD705F5AQ57824479-D33E915C-B15C-400D-AE03-A37A888A65D1Q57824505-45A5E28F-1FE6-4F0D-916B-E38A56BD0EAD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark Greer
@ast
Mark Greer
@en
Mark Greer
@es
Mark Greer
@nl
Mark Greer
@sl
type
label
Mark Greer
@ast
Mark Greer
@en
Mark Greer
@es
Mark Greer
@nl
Mark Greer
@sl
prefLabel
Mark Greer
@ast
Mark Greer
@en
Mark Greer
@es
Mark Greer
@nl
Mark Greer
@sl
P106
P21
P31
P496
0000-0003-3234-306X